Stock HLS HLS THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights HLS Therapeutics Inc.

Equities

HLS

CA40390B1094

Delayed Toronto S.E.
Other stock markets
 12:31:20 2024-07-03 pm EDT 		5-day change 1st Jan Change
3.65 CAD +3.11% Intraday chart for HLS Therapeutics Inc. +8.63% -7.59%
Jul. 02 National Bank on DRI Healthcare Trust's Xenpozyme Royalty Stream Acquisition MT
Jul. 02 HLS Therapeutics Sells Xenpozyme Royalty Interest to DRI Healthcare Trust MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
National Bank on DRI Healthcare Trust's Xenpozyme Royalty Stream Acquisition
MT
HLS Therapeutics Sells Xenpozyme Royalty Interest to DRI Healthcare Trust
MT
HLS Therapeutics Brief: Announcing Sale of its XENPOZYME Royalty Interest to DRI Healthcare Trust
MT
HLS Therapeutics Notes Role of Pharmaceutical Support Programs on Persistence with Clozapine Treatment in Quebec Study
MT
HLS Therapeutics Inc. Announces New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment
CI
HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance
MT
Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 9, 2023.
CI
HLS Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
HLS Therapeutics Brief: Q1 2024 revenue was US$12.5 million, Adjusted EBITDA was $2.7 million and cash from operations was $0.8 million
MT
HLS Therapeutics Inc Updates Consolidated Revenue Guidance for the Full Year 2024
CI
Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 9, 2023.
CI
Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 10, 2022.
CI
HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA
CI
HLS Therapeutics Reports Q4 2023 Net Loss of US$5.4 Million; Provides 2024 Outlook, Credit Agreement Update
MT
HLS Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
HLS Therapeutics Brief: Q4 2023 and fiscal 2023 product sales in Canada increased 11% and 10%, respectively, in CAD, compared to same periods in 2022
MT
HLS Therapeutics Brief: Q4 2023 revenue was US$15.9 million, Adjusted EBITDA was $5.3 million and cash from operations was $3.7 million
MT
HLS Therapeutics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2024
CI
HLS Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
HLS Therapeutics Says Vascepa Now Reimbursed by British Columbia's Provincial Drug Plan
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HLS Stock
  4. News HLS Therapeutics Inc.
  5. Highlights